» Articles » PMID: 8852400

Role of Interleukin-2 in Human Hematological Malignancies

Overview
Journal Med Oncol
Publisher Springer
Specialty Oncology
Date 1995 Sep 1
PMID 8852400
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical studies with Interleukin-2 (IL-2) in human hematologic malignancies were initiated in the late 1980s. Based on clinical studies on various solid tumors, and laboratory research on hematopoietic cells, IL-2 was shown to be effective in 150 acute myeloid leukemia (AML) patients mainly for maintenance therapy in first complete remission, or with residual blast cells in the marrow. IL-2 has also been shown to be effective in remission induction in 10 patients with chronic myeloid leukemia (CML). The role of IL-2 in lymphoma patients remains to be established. IL-2 alone or in combination with Interferon-alpha, may intensify remission and prolong disease-free survival when given post autologous bone marrow transplantation (BMT) to patients with lymphoma and myeloid leukemia, and to a lesser degree, to patients with acute lymphatic leukemia (ALL). IL-2 in combination with HLA-matched or mismatched peripheral blood lymphocytes was also used post autologous BMT in preliminary studies. IL-2 was administered with or without peripheral blood lymphocytes, for prevention of relapse post T-cell-depleted allogeneic BMT in CML, ALL and AML, with encouraging results. The same strategy was shown to be effective in the reinduction of remission in patients with CML, who relapsed post BMT.

Citing Articles

Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.

Greil R, Hutterer E, Hartmann T, Pleyer L Cell Commun Signal. 2017; 15(1):5.

PMID: 28100240 PMC: 5244547. DOI: 10.1186/s12964-016-0155-9.


Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia.

Lange B, Yang R, Gan J, Hank J, Sievers E, Alonzo T Pediatr Blood Cancer. 2011; 57(3):398-405.

PMID: 21681921 PMC: 3172052. DOI: 10.1002/pbc.22966.

References
1.
van Rhee F, Lin F, Cullis J, Spencer A, Cross N, Chase A . Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood. 1994; 83(11):3377-83. View

2.
Lotzova E, Savary C, Herberman R . Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol. 1987; 138(8):2718-27. View

3.
Nagler A, Ackerstein A, Barak V, Slavin S . Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-alpha 2a. J Hematother. 1994; 3(1):75-82. DOI: 10.1089/scd.1.1994.3.75. View

4.
Sullivan K, Weiden P, Storb R, Witherspoon R, Fefer A, Fisher L . Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989; 73(6):1720-8. View

5.
Verdonck L, van Heugten H, Giltay J, Franks C . Amplification of the graft-versus-leukemia effect in man by interleukin-2. Transplantation. 1991; 51(5):1120-4. View